Day One Biopharmaceuticals, Inc.
DAWNDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
4
Next Catalyst
Feb 2027
Market Overview
Stock performance and key metrics
4 upcoming, 0 past
How DAWN's past catalysts played out
Chemotherapeutic Agent
Low-grade Glioma
Tovorafenib
Low-grade Glioma
Emi-Le
Triple Negative Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Chemotherapeutic Agent | Phase 3 | Low-grade Glioma | - | - |
Tovorafenib | Phase 3 | Low-grade Glioma | - | - |
Emi-Le | Phase 2 | Triple Negative Breast Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Day One Biopharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Day One Biopharmaceuticals, Inc.'s (DAWN) pipeline across Phase 3, Phase 2. Its lead program is Chemotherapeutic Agent (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Day One Biopharmaceuticals, Inc.'s next FDA catalyst?→
Day One Biopharmaceuticals, Inc.'s (DAWN) next tracked catalyst is a Phase 2 expected February 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DAWN biotech catalysts?→
Add DAWN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Day One Biopharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.